Japan Approves Leqembi, Its First Alzheimer’s Drug Developed By Biogen And Eisai
Japan's approval of Leqembi, developed jointly by US and Japanese pharma companies, comes two months after it was endorsed by the FDA
TOKYO — Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies. It's the first drug for treatment of the disease in a country with a rapidly aging population.
Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration.
Leqembi is for patients with mild dementia and other symptoms in the early stages of Alzheimer's disease, and the first medicine that can modestly slow their cognitive decline.
Prime Minister Fumio Kishida, who announced Japan's approval of Leqembi on Monday, called it “a breakthrough” and said that the “treatment of dementia has now entered a new era.”
Kishida has pledged to step up support for the growing number of dementia patients and their families and is due to launch a panel this week to discuss measures for a dementia-friendly society.
According to the health ministry, Japan's number of dementia patients who are 65 years of age or older will rise to 7 million in 2025, from the current 6 million.
- Biogen Stock Falls Following FDA Approval of Alzheimer’s Drug
- Biogen To Cut 1,000 Jobs as it Prepares to Launch Alzheimer’s Drug
- FDA Approves New Drug to Slow Alzheimer’s Dementia Progression
- New Alzheimer’s Drug Struggles To Get Insurance Coverage
- New Alzheimer’s Drug on the Way, Could Arrive in a Few Months
- Breakthrough Alzheimer’s Drug Slows Disease 35%: Study
The drug, however, does not work for everyone and — as with other Alzheimer's drugs that target plaques in the brain — can cause dangerous side effects such as brain swelling and bleeding in rare cases.
Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures.
The drug will be partially covered by health insurance and is expected to be ready for clinical use by the end of the year. The price is yet to be decided but is expected to be expensive, Kyodo News agency reported.
Eisai is committed to delivering Leqembi to people who need it and their families “as a new treatment,” said Haruo Naito, the company’s CEO.
“We aim to create impact on issues surrounding dementia in Japanese society," he said.
- The Top Wellness Trends in Sleep, Food and MoreHealth
- Michael Bolton Recovering From Brain Tumor Removal, Taking ‘Temporary Break’Entertainment
- Measles Outbreak Linked to Iconic Children’s HospitalHealth
- Toxic Yellow Oleander Found in Some Weight Loss Supplements, FDA WarnsHealth
- Goop’s New Year’s ‘Detox’ Is as Restrictive as You’d ThinkHealth
- Florida’s Bid for Cheaper Drugs Approved by FDA, but Some Aren’t ThrilledHealth
- Ozempic, Wegovy, Less Likely to Cause Suicidal Thoughts Than Other Weight Loss Drugs: NIH StudyHealth
- Costco Manager’s Phone Call to Late Employee Likely Saved Ohio Man’s LifeNews
- Bootleg Alcohol Kills 3, Injures 20Health
- Wearing Hearing Aids May Help You Live Longer: StudyHealth
- Deadly Lung Condition Can Be Slowed by This SuperfoodHealth
- Do Doctors With Addictions Have a Right to Privacy When They Seek Out Treatment?Health
